Charles H. Heldebrant
Chief Scientific Officer
PSC Biotech
Abeona Therapeutics
United States of America
Biography
Dr. Heldebrant is the Chief Scientific Officer of PSC Biotech. He has accumulated experience in over 28 years of increasingly responsible and varied positions at Alpha Therapeutic Corporation, successively owned by Abbott, Green Cross, and now Grifols, where he oversaw the development, FDA licensing, and production of the company’s alpha-1 antitrypsin (“AAT”) product which was eventually sold to Baxter. Subsequently he was with National Genetics Institute/LabCorp for over four years. He has extensive experience in biological and pharmaceutical product development, regulatory affairs, quality systems, process design, equipment and process validation, analytical methods validation, and computer validation. Dr. Heldebrant holds 14 patents and is the author or co-author of 31 scientific/technical papers and over 40 extracts.
Research Interest
biological and pharmaceutical product development
